Subscribe today to receive notice of our latest thought leadership, articles, and updates.
Insights
Clinical Connection
Clinical impact on workers' compensation and auto no-fault
Recent updates
|
May 19, 2025 · Clinical Team
On January 30, 2025, Axsome Therapeutics, Inc. announced the U.S. Food and Drug Administration approval of Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo is not indicated for the prevention of migraine attacks or treatment of cluster headache. Read more... |
|
|
April 08, 2025 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced the approval of Journavx™ (suzetrigine) for the treatment of moderate-to-severe acute pain in adults. Read more... |
|
May 07, 2024 · Clinical Team
On May 4, 2024, the U.S. Food and Drug Administration (FDA) reported that Breckenridge Pharmaceutical, Inc (Breckenridge) issued a retail level recall of duloxetine delayed-release capsules. Read more... |
|
|
April 25, 2024 · Clinical Team
Although topical lidocaine is often prescribed to relieve pain for many injured persons, there are still risks associated with using lidocaine products. Overuse and overapplication of such products may lead to seizures, irregular heartbeat, and breathing difficulties. Injured persons are strongly advised to carefully read medication labels and consult with their healthcare providers (including pharmacists) about using topical analgesics as well as any other over-the-counter or prescription medications they take. Read more... |
|
|
January 17, 2024 · Clinical Team
The U.S. Food and Drug Administration (FDA) reported that Dr. Reddy’s voluntarily recalled one lot of tizanidine 4 mg tablets at the consumer level as a precautionary measure. Tizanidine is a skeletal muscle relaxant commonly prescribed for the treatment of muscle spasticity. Read more... |
|
|
December 06, 2023 · Clinical Team
FDA warns that the antiseizure medications levetiracetam and clobazam may cause life-threatening adverse reaction. Read more... |
|
|
November 29, 2023 · Clinical Team
In January, Optum clinical programs will adopt revised morphine equivalent dose (MED) conversion factors for the opioid analgesics hydromorphone, methadone, and tramadol to correlate with CDC Guidelines. However, these modifications are predicted to have little effect on Optum risk identification and clinical review programs. Read more... |
|
|
November 17, 2023 · Clinical Team
Opvee® (nalmefene) nasal spray now available for emergency treatment of opioid overdoses, but currently non-formulary on all standard formularies until review by Optum P&T Committee. One unit of Opvee will likely be allotted per year by CMS. For WCMSAs, exposure for opioid antagonists like Opvee is unlikely to be significant. Read more... |
Page 1 of 4